Would you treat a postmenopausal women with high grade T2N0 ER-, PR+, HER2- invasive ductal carcinoma with upfront surgery or neoadjuvant chemotherapy?
ER <1%; PR 45%, Her2 negative by IHC and FISH. Grade 3, Ki67: 80%.
Community PollStarted
Would you treat a postmenopausal women with high grade T2N0 ER-, PR+, HER2- invasive ductal carcinoma with upfront surgery or neoadjuvant chemotherapy?
38 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic Rochester
Answered on · Updated on
I'd conduct a conversation about NAC, but it isn't clear to me that NAC would change anything for this patient. PR 45% does not qualify as "functionally triple negative" in my book, so I'd consider this still HR+. I would not offer more than AC-T whether NAC or adjuvant. Additionally, I wouldn't off...
Join for free or sign in to see the full answer